Ascendis Pharma A/S (ASND)
228.01
-6.98
(-2.97%)
USD |
NASDAQ |
Feb 25, 16:00
228.01
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma Research and Development Expense (Quarterly) : 88.09M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Novo Nordisk A/S | 2.283B |
| Evaxion AS | 2.158M |
| DBV Technologies SA | 26.82M |
| Cellectis SA | 19.34M |
| Biodexa Pharmaceuticals Plc | -- |